Searchable abstracts of presentations at key conferences in endocrinology

ea0019p9 | Bone | SFEBES2009

Effects of adiponectin on the osteosarcoma cell line Saos-2

Pacheco-Pantoja EL , Sodi R , Gallagher J , Fraser WD

Adiponectin, the most abundant peptide hormone secreted from adipose tissue, has been negatively correlated with obesity and can induce varying responses on bone. There are significant discrepancies in the published data, showing increased, decreased or no effects on bone turnover.We investigated the effects of adiponectin on the human osteosarcoma cell line Saos-2. After culture with varying concentrations of adiponectin (10–100 nM), supernatants w...

ea0011p11 | Bone | ECE2006

PTH and phosphate circadian rhythms are altered in adult growth hormone deficient patients with low bone mineral density

White HD , Ahmad AM , Durham BH , Fraser WD , Vora JP

Adult Growth Hormone Deficiency (AGHD) is associated with osteoporosis. PTH is secreted in a circadian rhythm and temporal fluctuations in PTH concentration, particularly at night, appear to be important in the regulation of bone turnover. Serum phosphate is an important determinant of PTH, with changes in phosphate preceding fluctuations in PTH concentration. We examined the difference in PTH and phosphate circadian rhythmicity in AGHD patients with normal and reduced bone mi...

ea0011p12 | Bone | ECE2006

Oral phosphate therapy used as an adjunct to growth hormone in adult growth hormone deficiency results in greater changes in bone mineral density compared with growth hormone replacement alone

White HD , Ahmad AM , Durham BH , Fraser WD , Vora JP

Adult Growth Hormone Deficiency (AGHD) is associated with reduced bone mineral density (BMD) and bone turnover. Abnormalities in PTH circadian rhythmicity, including blunted nocturnal rise in PTH concentration have been reported in AGHD and may underlie the pathogenesis of osteoporosis. Serum phosphate is an important regulator of PTH, with changes in phosphate concentration preceding fluctuations in PTH. We examined the effect of oral phosphate therapy on PTH circadian rhythm...

ea0020p234 | Bone/Calcium | ECE2009

The circulating concentration of adiponectin in post-menopausal women with and without osteoporosis and its association with body mass index and biochemical markers of bone metabolism

Sodi R , Hazell MJ , Durham BH , Rees C , Ranganath LR , Fraser WD

Introduction: There is increasing evidence suggesting that adiponectin plays a role in the regulation of bone metabolism. We have studied the changes in the circulating concentration of adiponectin in lean and obese post-menopausal women with and without osteoporosis and its association with a marker of bone formation – type 1 procollagen amino-terminal pro-peptide (P1NP) and a marker of bone resorption – type 1 collagen C-telopeptide (βCTX).<p class="abstex...

ea0019p4 | Bone | SFEBES2009

Effects of five gut hormones on osteoblastic-like cell lines

Pacheco-Pantoja EL , Ranganath L , Wilson P , Gallagher J , Fraser WD

Gut hormones are gastro-entero-pancreatic hormones released during the normal physiological response to feeding/fasting. Adequate nutrient intake and normal gastrointestinal function are critical to bone health, which can be under constant repair and remodelling. Gut hormones may integrate a connection between food intake and bone turnover.We studied the effects of five gut hormones, glucose-dependent insulinotropic polypeptide (GIP), glucagon-like pepti...

ea0015p14 | Bone | SFEBES2008

Effects of 6 months strontium ranelate administration on phosphocalcium metabolism in postmenopausal women with reduced bone density

Joshi AA , Ahmad AM , Whittingham P , Gupta V , Hamilton A , Durham BH , Fraser WD , Vora JP

Introduction: Strontium ranelate (SR) is a dual action bone agent that increases bone formation and reduces bone resorption. Previous long term studies with SR have demonstrated minimal reductions in parathyroid hormone (PTH) and adjusted calcium (ACa) levels with increase in phosphate (PO4) concentrations, but the exact mechanism of action of SR remains unclear. Postmenopausal women with low bone mineral density (BMD) have relatively high circulating PTH concentrat...

ea0013p9 | Bone | SFEBES2007

Diurnal variation in total and bioavailable oestradiol in aging men with osteoporosis

Joshi AA , Joseph F , Robinson AC , Fraser WD , Diver MJ , Vora JP

Introduction: The effect of oestrogens on the male skeleton has been demonstrated in a number of studies and oestradiol (E2) plays an important role in regulating bone mineral density (BMD). The concentration of bioavailable oestradiol (BE), rather than total oestradiol (TE), is associated with bone loss in elderly men.Oestradiol circulates in the bloodstream in one of three forms: bound to SHBG; bound to albumin; and unbound/free. The albumin-bound plus the free fraction comp...

ea0012oc15 | Placenta, bone and genetics | SFE2006

Preliminary results from the PRISM study: a multicentre randomised controlled trial of intensive vs. symptomatic management for Paget’s disease of bone

Ralston SH , Langston AL , Campbell MK , MacLennan G , Selby PL , Fraser WD

Bisphosphonates are the treatment of choice for Paget’s disease of bone (PDB). However, long-term effects on complications are unknown. The PRISM trial was a randomised controlled trial comparing symptomatic management and intensive bisphosphonate therapy for PDB, and involved 1324 patients followed for a median of 32 months (range 12–48). Patients allocated to symptomatic therapy (n=663) were untreated unless they had bone pain, at which point they received a...

ea0011p25 | Bone | ECE2006

Effects of growth hormone administration on parathyroid hormone sensitivity and bone mineral metabolism in established osteoporosis

Joseph F , Ahmad A , White HD , Joshi A , Durham B , Vinjamuri S , Ashawesh K , Fraser WD , Vora JP

Introduction: The beneficial effect of GH replacement on bone in AGHD patients is mediated by improvements in target organ sensitivity to PTH and phosphocalcium metabolism. In aging women with established osteoporosis, GH and IGF-1 concentrations are lower and administration of GH has been shown to increase bone turnover and BMD, but the mechanisms remain unclear.Methods: Fourteen postmenopausal women (63.4±2.1 years; mean BMD T score ± ...